US court invalidates key Heron Therapeutics patents on CINVANTI; company plans to appeal.

A U.S. District Court ruled that key patents held by Heron Therapeutics for its CINVANTI injectable emulsion are invalid. This decision does not affect prior settlements related to CINVANTI or APONVIE. Heron plans to appeal the ruling to the U.S. Court of Appeals for the Federal Circuit, aiming to defend its intellectual property rights. The company expressed disappointment but remains committed to pursuing all legal remedies, including equitable relief if necessary.